Vancomycin HCI vials

Vancomycin HCI vials
Product Description

Vancomycin hydrochloride (HCI) is a glycopeptide antibiotic active against a wide variety of aerobic Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroids, enterococci, (e.g. Enterococcus faecalis), Streptococcus bovis and viridans group streptococci.

Indication: Used in the treatment of patients with severe and/or methicillin-resistant staphylococcal infections (endocarditis, bone infections, lower respiratory tract infections, septicemia and skin structure infections) and treatment of preoperative prophylaxis of streptococcal or diphteroid endocarditis where other antibiotics cannot be used due to intolerance or drug resistance. It may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis.

Application: Administered as intravenous infusions for systemic therapy. May be administered orally for treatment of antibiotic-associated pseudomembranous colitis.

Shelf-life: 24 months

Storage conditions: Between 15-25°C (59-77°F) depending on territory

For further information contact us at [email protected] 

or access our product sheet online https://xellia.com/products/Vancomycin%20HCI%20vials/

Xellia Pharmaceuticals ApS

  • DK
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Finished Formulation products Distributor/Buyer

Xellia Pharmaceuticals ApS

  • DK
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Finished Formulation products Distributor/Buyer

More Products from Xellia Pharmaceuticals ApS (21)

  • Bacitracin vials

    Product Bacitracin vials

    Bacitracin is comprised of a polypeptide complex and bacitracin A is the major component in this complex active against a variety of Gram-positive bacteria and a few Gram-negative bacteria, however only staphylococcal infections qualify for the systemic therapy.

    Indi...
  • Colistimethate sodium lyophilized vials

    Product Colistimethate sodium lyophilized vials

    Colistimethate sodium is a prodrug of colistin, which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and especially Pseudomonas aeruginosa.

    Indication:&nbs...
  • Daptomycin RT

    Product Daptomycin RT

    Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.
    Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus aureus&nbs...
  • Daptomycin vials

    Product Daptomycin vials

    Daptomycin is a lipopeptide antibacterial agent active against Gram-positive bacteria.

    Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of Gram-positive bacteria such as Staphylococcus au...
  • Micafungin vials

    Product Micafungin vials

    Micafungin is a semisynthetic lipopeptide from the echinocandin class of antifungal agents. Micafungin is active against most isolates of the following Candida species such as Candida albicans, Candida glabrata, Candida guiliermondii, Candida krusei, Candida parapsilosis and Candida tropicalis.
    ...
  • Polymyxin B vials

    Product Polymyxin B vials

    Polymyxin B is a mixture of the sulfates of polypeptide antibiotics active against Gram-negative bacteria.

    Indication: Used in the treatment of patients with acute urinary, meningeal or blood-stream infections due to susceptible strains such as Pseudomonas aerugino...
  • Voriconazole vials

    Product Voriconazole vials

    Voriconazole is a broad spectrum triazole antifungal agent.

    Indication: Used in the treatment of patients with progressive, possibly life-threatening fungal infections such as candidaemia in non-neutropenic patients, invasive candidiasis in skin, abdomen, kidney, bladd...
  • Colistimethate sodium dry-filled vials

    Product Colistimethate sodium dry-filled vials

    Colistimethate sodium is a prodrug of colistin which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Indication: Used in the treatment of patients with serious infectio...
  • Vancomycin Injection, Ready to Use

    Product Vancomycin Injection, Ready to Use

    Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, such as Staphylococcus aureus and Staphylococcus epidermidis (including susceptible methicillin-resistant strains), but also active against corynebacterium, ent...
  • Amphotericin B

    Product Amphotericin B

    Amphotericin B is a mixture of polyenes active against a wide variety of fungi e.g. Aspergillus, Candida and Cryptococcus species.

    Indication: Used in the treatment of severe, invasive, potentially life-threatening fungal infections (mycosis) typically in immunocompromised patients. q...
  • Bacitracin

    Product Bacitracin

    Bacitracin is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci.

    Indication: Used locally for the treatment of infections of the skin, ear and eye or for intramuscular use in infants for the...
  • Bacitracin zinc

    Product Bacitracin zinc

    Bacitracin zinc is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci. The zinc complex adds stability to the component, making bacitracin zinc more stable compared to bacitracin.

    Indication: Used in the treatm...

Xellia Pharmaceuticals ApS resources (9)

  • News Xellia Pharmaceuticals welcomes Michael Kocher as its new Chief Executive Officer

    Copenhagen, Denmark, 2 October 2023 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies, today welcomes Michael Kocher as its new Chief Executive Officer. With more than a decade of experience in commercial leadership roles at Novartis and Sandoz, Michael Kocher has significant expertise in the complexities of the global pharmaceutical landscape. His tenure at Sandoz, where he served as Global Head of Commercial Operations and subsequently as Global Head of B2B, underscored his pivotal role in transforming the company into a leading global partner within the industry. A native of Germany and a trained chemist, Michael Kocher's expertise and vision align with Xellia Pharmaceuticals' commitment to delivering anti-infective treatments and critical care therapies.
  • Technical Data Xellia Corporate Introduction

    Xellia Pharmaceuticals is a specialty pharmaceutical company developing,manufacturing and commercializing anti-infective treatments againstserious and often life-threatening bacterial and fungal infections. Xellia isa world-leading trusted supplier of several important established antiinfectivedrugs, comprising active pharmaceutical ingredients as well asfinished dosage forms, where the majority are injectable drug products.Headquartered in Copenhagen, Denmark and owned by Novo HoldingsA/S, Xellia Pharmaceuticals has more than 1800 employees globally.From state-of-the-art manufacturing sites in the U.S., China, Denmarkand Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticalsexcels within innovative product development to deliver high qualityproducts to its customers.
  • News Xellia Pharmaceuticals announces the appointment of Michael Kocher as its new Chief Executive Officer

    Copenhagen, Denmark, 14 June 2023 - Xellia Pharmaceuticals (‘Xellia’), a global leading pharmaceutical company, announces the appointment of Michael Kocher as its new Chief Executive Officer.

    Michael Kocher, Head of Global B2B-Business in Sandoz and Country President of Novartis in Austria is appointed as CEO of Xellia starting 1 October 2023 where he will replace Carl-Åke Carlsson, who has been with Xellia as CEO since 2008.

  • Video Xellia Manufacturing Collage 2023

    Xellia Manufacturing Collage 2023
  • News Xellia Pharmaceuticals Joins End Drug Shortages Alliance

    Copenhagen, Denmark and Buffalo Grove, IL, USA - 16 December 2022 Xellia Pharmaceuticals announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care. 
  • Video Sustainability and AMR advocacy

    Sustainability and AMR advocacy
  • News SOS Children’s Villages and Xellia Pharmaceuticals End Year Report 2022

    We are very pleased to share the update on our partnership with SOS Children’s Villages, with the release of the End Year Report 2022– which provides an overview of the highlights of the year on the support initiatives Xellia has focused on with SOS Children’s Villages, to help families living in hardship. In addition to Xellia’s corporate partnership funding which focuses on Eldoret, Kenya – our colleagues have shown immense engagement raising funds for supplementary needs and projects for both SOS Children’s Villages in Eldoret, Kenya and for other SOS Children’s Villages around the world which we have collaborated with.

    Xellia Pharmaceuticals’ support of the Family Strengthening Program surrounds the Programs’ focus on working jointly with community-based organizations, volunteers and local authorities to build effective support systems for struggling families through assisting with vital everyday needs. This can include mat...
  • Video Xellia and SOS Children’s Villages partnership

    Xellia and SOS Children’s Villages partnership
  • News Xellia Pharmaceuticals Reports 2022 Business Update and 2023 Outlook

    Copenhagen, Denmark, 18 April 2023 - Xellia Pharmaceuticals (‘Xellia’ or the ‘Group’), a specialty pharmaceutical company focusing on providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions, reports its business update for the year ending December 31, 2022 and outlook for 2023.